Document:

Standard Director Form

 Exhibit 10.18 
 VIA PHARMACEUTICALS, INC. 
 2004 STOCK PLAN 
 STOCK OPTION AGREEMENT 
 Unless
otherwise defined herein, the terms defined in the 2004 Stock Plan shall have the same defined meanings in this Stock Option Agreement. 
  

							
	 I.      NOTICE OF STOCK OPTION GRANT

			
	        Name:	  		 	
			
	        Address:	  		 	
	
	 The undersigned Optionee has been granted an Option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and
this Option Agreement, as follows:

				
	 Date of Grant
	  		 	 	  	
				
	 Vesting Commencement Date
	  		 	 	  	
				
	 Exercise Price per Share
	  	$	 	 	  	
				
	 Total Number of Shares Granted
	  		 	 	  	
				
	 Total Exercise Price
	  	$	 	 	  	
				
	 Type of Option:
	  		 	___  Incentive Stock Option	  	
				
		  		 	___  Nonstatutory Stock Option	  	
				
	 Term/Expiration Date:
	  		 	 	  	
				
	 Vesting Schedule:
	  		 		  	
	
	 This Option shall be 100% vested as of the vesting commencement date.

  
  
  
  
  
  
  
  
  
  

 Termination Period: 
 This Option shall be exercisable for three (3) months after Optionee ceases to be a Service Provider. Upon Optionee’s death or Disability, this Option may be exercised for one (1) year after Optionee
ceases to be a Service Provider. In no event may Optionee exercise this Option after the Term/Expiration Date as provided above. 
  

	II.	AGREEMENT 

 1.    
Grant of Option.     The Plan Administrator of the Company hereby grants to the Optionee named in the Notice of Grant (the “Optionee”), an option (the “Option”) to purchase the number of Shares set
forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the “Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by reference. Subject to
Section 15(c) of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan shall prevail. 
 If designated in the Notice of Grant as an Incentive Stock Option (“ISO”), this Option is intended to qualify as an Incentive Stock Option as
defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this Option shall be treated as a Nonstatutory Stock Option (“NSO”). 
  

	 	2.	Exercise of Option. 

 (a) Right to Exercise.
This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Grant and with the applicable provisions of the Plan and this Option Agreement. 
 (b) Method of Exercise. This Option shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A (the
“Exercise Notice”) which shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised, and such other representations and agreements as may be required by the Company. The
Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate
Exercise Price. 
 No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such exercise complies with
Applicable Laws. Assuming such compliance, for income tax purposes the Shares shall be considered transferred to the Optionee on the date on which the Option is exercised with respect to such Shares. 
 3.     Optionee’s Representations.     In the event the Shares have not been registered under the
Securities Act of 1933, as amended, at the time this Option is exercised, the Optionee shall, if required by the Company, concurrently with the exercise of all or any portion of this Option, deliver to the Company his or her Investment
Representation Statement in the form attached hereto as Exhibit B. 
  

 -2- 

 4.     Lock-Up Period.     Optionee hereby agrees that
Optionee shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or
indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other
securities) of the Company held by Optionee (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred eighty
(180) days following the effective date of any registration statement of the Company filed under the Securities Act. 
 Optionee agrees
to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or
the representative of the underwriters of Common Stock (or other securities) of the Company, Optionee shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection
with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section shall not apply to a registration relating solely to employee
benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may
impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period. Optionee agrees that any transferee of the Option
or shares acquired pursuant to the Option shall be bound by this Section. 
 5.     Method of
Payment.     Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of the Optionee: 
 (a) cash or check; 
 (b) consideration received by the Company under a formal cashless exercise program
adopted by the Company in connection with the Plan; or 
 (c) surrender of other Shares which, (i) in the case of Shares acquired from
the Company, either directly or indirectly, have been owned by the Optionee, and not subject to a substantial risk of forfeiture, for more than six (6) months on the date of surrender, and (ii) have a Fair Market Value on the date of
surrender equal to the aggregate Exercise Price of the Exercised Shares. 
 6.     Restrictions on
Exercise.     This Option may not be exercised until such time as the Plan has been approved by the shareholders of the Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration
for such shares would constitute a violation of any Applicable Law. 
 7.     Restrictions on
Shares.     Optionee hereby agrees that Shares purchased upon the exercise of the Option shall be subject to such terms and conditions as the Committee shall 

  

 -3- 

 
determine in its sole discretion, including, without limitation, restrictions on the transferability of Shares, the right of the Company to repurchase
Shares, and a right of first refusal in favor of the Company with respect to permitted transfers of Shares. Such terms and conditions may, in the Committee’s sole discretion, be contained in the Exercise Notice with respect to the Option or in
such other agreement as the Committee shall determine and which the Optionee hereby agrees to enter into at the request of the Company 
 8.     Non-Transferability of Option.     This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the
lifetime of Optionee only by Optionee. The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee. 
 9.     Term of Option.     This Option may be exercised only within the term set out in the Notice of
Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Option. 
  

	 	10.	Tax Obligations. 

 (a)    
Withholding Taxes.     Optionee agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or retaining Optionee) for the satisfaction of all Federal, state, local and foreign income
and employment tax withholding requirements applicable to the Option exercise. Optionee acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver Shares if such withholding amounts are not delivered at the time
of exercise. 
 (b)     Notice of Disqualifying Disposition of ISO Shares.     If the Option
granted to Optionee herein is an ISO, and if Optionee sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (1) the date two years after the Date of Grant, or (2) the date one year after
the date of exercise, the Optionee shall immediately notify the Company in writing of such disposition. Optionee agrees that Optionee may be subject to income tax withholding by the Company on the compensation income recognized by the Optionee.

 11.     Entire Agreement; Governing Law.     The Plan is incorporated herein by reference.
The Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Optionee with respect to the subject
matter hereof, and may not be modified adversely to the Optionee’s interest except by means of a writing signed by the Company and Optionee. This agreement is governed by the internal substantive laws but not the choice of law rules of
California. 
 12.     No Guarantee of Continued Service.     OPTIONEE ACKNOWLEDGES AND AGREES
THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). OPTIONEE
FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT 

  

 -4- 

 
AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH OPTIONEE’S RIGHT OR THE COMPANY’S
RIGHT TO TERMINATE OPTIONEE’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE. 
 Optionee acknowledges receipt of
a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety,
has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the
Administrator upon any questions arising under the Plan or this Option. Optionee further agrees to notify the Company upon any change in the residence address indicated below. 
  

									
	OPTIONEE	 		 	VIA PHARMACEUTICALS, INC.
			
	 	 		 	 
	Signature	 		 	By
		 		 	
			
	 	 		 	 
	Print Name	 		 	 Title

		 		 	
			
	 	 		 	
			
	 	 		 	
	 Residence Address
	 		 	

  

 -5- 

 EXHIBIT A 
 2004 STOCK PLAN 
 EXERCISE NOTICE 
 VIA Pharmaceuticals, Inc. 
 Address:_______________ 
 Attention: _______________ 
 1.    Exercise of Option. Effective as of today,
_____________, _____, the undersigned (“Optionee”) hereby elects to exercise Optionee’s option to purchase _________ shares of the Common Stock (the “Shares”) of VIA Pharmaceuticals, Inc. (the “Company”) under and
pursuant to the 2004 Stock Plan (the “Plan”) and the Stock Option Agreement dated ____________, ____ (the “Option Agreement”). 
 2.    Delivery of Payment. Optionee herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option Agreement, and any and all withholding taxes due in
connection with the exercise of the Option. 
 3.    Representations of Optionee. Optionee, without further action
on his or her part, by purchase of the Shares agrees to be deemed a party to, a signatory of and bound by the First Amended and Restated Stockholders’ Agreement dated March 31, 2006 as may be amended or restated from time to time and any
successor agreement thereto, (the “Stockholders’ Agreement”), and the Shares shall be subject to such rights and restrictions as contained therein. Participant acknowledges that he or she has received, read and understood the
Plan, the Option Agreement, the Stockholders’ Agreement, and this Exercise Notice and is familiar with their terms and provisions and agrees to abide by and be bound by their terms and conditions. 
 4.    Rights as Shareholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the
Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a shareholder shall exist with respect to the Optioned Stock, notwithstanding the exercise of the Option. The Shares shall
be issued to the Optionee as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend or other right for which the record date is prior to the date of issuance except as
provided in Section 13 of the Plan. 
 5.    Company’s Right of First Refusal. Before any Shares held by
Optionee or any transferee (either being sometimes referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first
refusal to purchase the Shares on the terms and conditions set forth in this Section (the “Right of First Refusal”). 
  

 (a)    Notice of Proposed Transfer. The Holder of the Shares shall deliver to
the Company a written notice (the “Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each proposed purchaser or other transferee (“Proposed
Transferee”); (iii) the number of Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to transfer the Shares (the “Offered Price”), and
the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s). 
 (b)    Exercise of Right
of First Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be
transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (c) below. 
 (c)    Purchase Price. The purchase price (“Purchase Price”) for the Shares purchased by the Company or its assignee(s) under this Section shall be the Offered Price. If the Offered Price includes
consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith. 
 (d)    Payment. Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding
indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the
Notice. 
 (e)    Holder’s Right to Transfer. If all of the Shares proposed in the Notice to be transferred
to a given Proposed Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section, then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price,
provided that such sale or other transfer is consummated within 120 days after the date of the Notice, that any such sale or other transfer is effected in accordance with any applicable securities laws and that the Proposed Transferee agrees in
writing that the provisions of this Section shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, a new Notice shall
be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. 
 (f)    Exception for Certain Family Transfers. Anything to the contrary contained in this Section notwithstanding, the
transfer of any or all of the Shares during the Optionee’s lifetime or on the Optionee’s death by will or intestacy to the Optionee’s immediate family or a trust for the benefit of the Optionee’s immediate family shall be exempt
from the provisions of this Section. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or other recipient shall receive and hold the Shares
so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance with the terms of this Section. 
  

 -2- 

 (g)    Termination of Right of First Refusal. The Right of First Refusal shall
terminate as to any Shares upon the earlier of (i) the first sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded.

 6.    Tax Consultation. Optionee understands that Optionee may suffer adverse tax consequences as a result of
Optionee’s purchase or disposition of the Shares. Optionee represents that Optionee has consulted with any tax consultants Optionee deems advisable in connection with the purchase or disposition of the Shares and that Optionee is not relying on
the Company for any tax advice. 
 7.    Restrictive Legends and Stop-Transfer Orders. 
 (a)    Legends. Optionee understands and agrees that the Company shall cause the legends set forth below or legends
substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws: 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.

 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER
OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE
BINDING ON TRANSFEREES OF THESE SHARES. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD NOT
TO EXCEED 180 DAYS FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY’S SECURITIES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER.

 (b)    Stop-Transfer Notices. Optionee agrees that, in order to ensure compliance with the restrictions
referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own
records. 
  

 -3- 

 (c)    Refusal to Transfer. The Company shall not be required (i) to
transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any
purchaser or other transferee to whom such Shares shall have been so transferred. 
 8.    Successors and Assigns.
The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set
forth, this Exercise Notice shall be binding upon Optionee and his or her heirs, executors, administrators, successors and assigns. 
 9.    Interpretation. Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Optionee or by the Company forthwith to the Administrator which shall review such dispute at its next
regular meeting. The resolution of such a dispute by the Administrator shall be final and binding on all parties. 
 10.    Governing Law; Severability. This Exercise Notice is governed by the internal substantive laws but not the choice of law rules, of California. In the event that any provision hereof becomes or is declared
by a court of competent jurisdiction to be illegal, unenforceable or void, this Exercise Notice will continue in full force and effect. 
 11.    Entire Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, the Option Agreement and the Investment Representation Statement constitute the entire
agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Optionee with respect to the subject matter hereof, and may not be modified adversely to the
Optionee’s interest except by means of a writing signed by the Company and Optionee. 
  

					
	 Submitted by:
 OPTIONEE
	  		 	 Accepted by:
 VIA PHARMACEUTICALS,
INC.

			
	 ____________________________________________
	  		 	____________________________________________
	 Signature
	  		 	By
			
	____________________________________________	  		 	____________________________________________
	 Print Name
	  		 	Title
			
	 Address:
	  		 	Address:
			
	____________________________________________	  		 	____________________________________________
			
	____________________________________________	  		 	____________________________________________
			
	____________________________________________	  		 	
		  		 	
		  		 	____________________________________________
		  		 	Date Received

 : 
  
  

 -4- 

 EXHIBIT B 
 INVESTMENT REPRESENTATION STATEMENT 
 OPTIONEE: 
 COMPANY:                     VIA PHARMACEUTICALS, INC. 
 SECURITY:                      COMMON STOCK 
 AMOUNT: 
 DATE: 
 In connection with the purchase of the above-listed Securities, the undersigned Optionee represents to the Company the following: 
 (a)    Optionee is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities.
Optionee is acquiring these Securities for investment for Optionee’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended
(the “Securities Act”). 
 (b)    Optionee acknowledges and understands that the Securities constitute
“restricted securities” under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of
Optionee’s investment intent as expressed herein. In this connection, Optionee understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Optionee’s representation
was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a
period of one year or any other fixed period in the future. Optionee further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is
available. Optionee further acknowledges and understands that the Company is under no obligation to register the Securities. Optionee understands that the certificate evidencing the Securities will be imprinted with any legend required under
applicable state securities laws. 
 (c)    Optionee is familiar with the provisions of Rule 701 and Rule 144,
each promulgated under the Securities Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the satisfaction of
certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the grant of the Option to the Optionee, the exercise will be exempt from registration under the Securities Act. In the event the Company
becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, ninety (90) days thereafter (or such longer period as any market stand-off agreement may require) the Securities exempt under
Rule 701 

  

 
may be resold, subject to the satisfaction of certain of the conditions specified by Rule 144, including: (1) the resale being made through a
broker in an unsolicited “broker’s transaction” or in transactions directly with a market maker (as said term is defined under the Securities Exchange Act of 1934); and, in the case of an affiliate, (2) the availability of
certain public information about the Company, (3) the amount of Securities being sold during any three month period not exceeding the limitations specified in Rule 144(e), and (4) the timely filing of a Form 144, if applicable.

 In the event that the Company does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold
in certain limited circumstances subject to the provisions of Rule 144, which requires the resale to occur not less than one year after the later of the date the Securities were sold by the Company or the date the Securities were sold by
an affiliate of the Company, within the meaning of Rule 144; and, in the case of acquisition of the Securities by an affiliate, or by a non-affiliate who subsequently holds the Securities less than two years, the satisfaction of the conditions
set forth in sections (1), (2), (3) and (4) of the paragraph immediately above. 
 (d)    Optionee further
understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required; and that,
notwithstanding the fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and
otherwise than pursuant to Rules 144 or 701 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in
such transactions do so at their own risk. Optionee understands that no assurances can be given that any such other registration exemption will be available in such event. 
  

	
	Signature of Optionee:
	
	 ________________________________________

	
	Date: _____________________________, ______

  

 -2-Conversion Agreement

 Exhibit 10.19 
 CONVERSION AGREEMENT 
 THIS
CONVERSION AGREEMENT (the “Agreement”) is made and entered into on the 11th day of May, 2007, by and between CORAUTUS GENETICS INC., a
Delaware corporation (the “Company”), and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (“BSC”). 
 WHEREAS, the Company has issued to BSC One Million Three Hundred Eighty-Five Thousand Three Hundred Seventy-Seven (1,385,377) shares of the Company’s Series D Preferred Stock (“Series D Preferred
Shares”) pursuant to that certain Investment Agreement dated July 30, 2003, and the Certificate of Designation of Preferences and Rights of Series D Preferred Stock dated and filed with the Secretary of State of the State of Delaware
on July 29, 2003 (“Series D Designation”); and 
 WHEREAS, pursuant to Series D Designation, the
Series D Preferred Shares currently are convertible into 1,420,339 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”); and 
 WHEREAS, the Company has issued to BSC Two Million Four Hundred Seventy-Five Thousand Six Hundred Fifty-Nine (2,475,659) shares of the
Company’s Series E Preferred Stock (“Series E Preferred Shares” and together with the Series D Preferred Shares, the “Preferred Shares”) pursuant to that certain Recapitalization Agreement, dated June 30,
2006, as amended October 31, 2006 (“Recapitalization Agreement”), and the Certificate of Designation of Preferences and Rights of Series E Preferred Stock dated and filed with the Secretary of State of the State of Delaware on
June 29, 2006 (“Series E Designation”); and 
 WHEREAS, pursuant to the Series E Designation the
Series E Preferred Shares currently are convertible into 2,475,659 shares of Common Stock; and 
 WHEREAS, pursuant to the
Series E Designation the holder of the Series E Preferred Shares is entitled to receive a stock dividend with value equal to the annual rate of 6% of the Series E Preferred Shares original issuance price; and 
 WHEREAS, the Company’s Board of Directors declared a dividend of Series E Preferred Stock convertible into 74,270 shares of Common Stock
and payable to the holders of Series E Preferred Shares (“Dividend”); and 
 WHEREAS, pursuant to that certain
Agreement and Plan of Merger and Reorganization, by and among the Company, VIA Pharmaceuticals, Inc. (“VIA”), and Resurgens Merger Corp., dated February 7, 2007, the Company has agreed to issue Common Stock to the stockholders of VIA
(“Issuance”) upon the closing date of the merger transaction contemplated thereby (“Merger”); and 
 WHEREAS,
pursuant to the Series D Designation and the Series E Designation, the Series D Preferred Shares and Series E Preferred Shares are entitled to conversion price adjustments upon the issuance of capital stock of the Company for
consideration to the Company below a certain specified price, subject to limitations set forth in the Recapitalization Agreement; and 

 WHEREAS, after giving effect to the Dividend, the Issuance and the corresponding conversion price
adjustments, the Series D Preferred Shares and the Series E Preferred Shares are convertible into 5,205,173 and 3,926,042 shares of Common Stock, respectively; and 
 WHEREAS, the Company and BSC desire to undertake a conversion of the Preferred Shares, whereby BSC shall convert all of the Preferred Shares for
9,131,215 shares of Common Stock effective immediately prior to the consummation of the Merger (“Effective Time”); and 
 WHEREAS, the Company and BSC desire to set forth the registration rights with respect to the Conversion Shares (as below defined); and 
 WHEREAS, the Company and BSC desire to terminate certain agreements between the parties. 
 NOW
THEREFORE, in consideration of the premises set forth above, the promises and the covenants hereinafter contained and other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 
  

	1.	CONVERSION OF PREFERRED SHARES. 

 1.1 Conversion
of Preferred Shares for Common Stock. At the Effective Time, BSC shall convert the Preferred Shares into 9,131,215 shares of Common Stock (“Conversion Shares”). 
 1.2 Stock Certificate. At the Effective Time, the Company shall cancel all outstanding certificates evidencing the Preferred Shares and
subsequently shall deliver to BSC a certificate reflecting the issuance of the Conversion Shares. 
 1.3 Termination of Preferences and
Rights of the Preferred Shares. As of the Effective Time, all of the preferences and rights of the Preferred Shares granted pursuant to the Series D Designation and Series E Designation shall be forever terminated and extinguished.

  

	2.	ADDITIONAL AGREEMENTS AND COVENANTS 

 2.1
Termination of Certain Agreements. At the Effective Time, the following agreements shall be terminated, and no party shall have any continuing rights or obligations thereunder: 
  

	 	•	 	 That certain Investor Rights Agreement by and between the Company and BSC, dated July 30, 2003; 

  

	 	•	 	 That certain Investment Agreement by and between the Company and BSC, dated July 30, 2003; 

  

	 	•	 	 That certain Investment Agreement by and between the Company and BSC, dated June 27, 2005; 

  

 2 

	 	•	 	 That certain Registration Rights Agreement by and between the Company and BSC, dated June 27, 2005; and 

  

	 	•	 	 The Recapitalization Agreement. 

 2.2 Registration Rights of Conversion Shares. 
 (i) Demand Registration 
 If at any time after the 270th day following the Effective Time BSC shall request the Company in writing (each, a “Demand”) to register under the Securities Act of 1933, as amended (“Securities Act”), a specified number of Conversion Shares, the
Company shall use commercially reasonable efforts to effect the registration under the Securities Act of the Conversion Shares which the Company has been so requested to register as soon as reasonably practicable so as to permit the sale thereof,
and in connection therewith shall prepare and file a registration statement with the SEC under the Securities Act (“Registration Statement”) to effect such registration; provided, that each such request shall (a) specify the number of
shares of Conversion Shares intended to be offered and sold, (b) describe the nature or method of the proposed offer and sale thereof and (c) contain the undertaking of BSC to provide all such information and materials and take all such
action as may be required in order to permit the Company to comply with all applicable requirements of the SEC and to obtain any desired acceleration of the effective date of such Registration Statement; provided, further, that with respect to any
Demands under this Section 2.2(i), the anticipated aggregate offering price of the Conversion Shares covered by such registration exceeds $2,000,000 (net of underwriting discounts and commissions). 
 (ii) Selection of Underwriter(s) 
 If
the registration pursuant to Section 2.2(i) relates to an underwritten offering, the managing or lead underwriter(s) shall be an underwriter(s) of nationally recognized standing selected by the Company, which shall be reasonably acceptable to
BSC; provided, if the foregoing is inconsistent with any agreement that is in effect between the Company and an underwriter on the date hereof (but not as such agreement may be hereafter amended), then BSC shall have the right to approve the co-lead
manager. 
 (iii) Priority in Demand Registration 
 If a registration pursuant to Section 2.2(i) involves an underwritten offering, and the managing or lead underwriter(s) shall advise BSC in writing (a copy of which shall be provided to the Company by BSC) that,
in its or their reasonable commercial judgment, the number of Conversion Shares requested to be included in such registration by BSC exceeds the number which can be sold in such offering within a price range acceptable to BSC, the Company shall
include in such registration the number of securities that the Company is so advised can be sold in such offering, as follows: (i) first, the Conversion Shares proposed to be included by BSC, (ii) second, the securities requested to be
registered by the Company, unless otherwise provided in an agreement between the Company and another person(s), and (iii) third, the securities of any other person(s) proposed to be included in such registration, in accordance, as to the
priorities among such other person(s), with the rights contained in the respective agreements into which such person(s) and the Company have entered. 
  

 3 

 (iv) Limits on Demand Registrations 
 The Company shall not be required to effect any registration pursuant to Section 2.2(i) or 2.2(vi) after one Demand requested by BSC pursuant to Section 2.2(i)
and/or 2.2(vi) shall have been effected. 
 (v) Withdrawal 
 BSC shall have the right to request withdrawal of any Registration Statement filed with the SEC pursuant to Section 2.2(i) or Section 2.2(vi) (and the Company
shall so withdraw such Registration Statement) so long as such Registration Statement has not become effective, provided that, in such case, BSC shall pay all related out-of-pocket Registration Expenses (as defined below in Section 2.2(xi))
reasonably incurred by the Company unless a Registration Statement shall be effected pursuant to Section 2.2(i) or Section 2.2(vi) within 270 days after such withdrawal. 
 (vi) Shelf Registration 
 If at any time after the 270th day following the Effective Time BSC shall request to the Company in writing, the Company shall use commercially reasonable efforts to file and cause to be declared effective a “shelf’ Registration Statement on any appropriate
form pursuant to Rule 415 (or similar rule that may be adopted by the SEC) under the Securities Act for Conversion Shares, which form shall be available for the sale of the Conversion Shares in accordance with the intended method or methods of
distribution thereof. The Company agrees to use commercially reasonable efforts to keep such Registration Statement continuously effective and usable for resale of Conversion Shares, for a period of twenty-four months from the date on which the SEC
declares such Registration Statement effective or such shorter period which will terminate at such time as BSC has sold all the Conversion Shares covered by such Registration Statement; provided, however, that the Company may elect that such
Registration Statement not be filed or usable during any Blackout Period (as defined in Section 2.2(x)(ii)). BSC shall be entitled to a total of one “shelf’ registration pursuant to this Section 2.2(vi), which shall count as one
Demand for purposes of the limitations on Demands set forth in Section 2.2(iv). 
 (vii) Effective
Registration Statement 
 A registration requested pursuant to Section 2.2(i) or 2.2(vi)shall not be deemed to be effected if (a) a Registration
Statement with respect thereto shall not have become effective under the Securities Act and remained effective for at least 90 days or until the completion of the distribution of the Conversion Shares thereunder, whichever is earlier (including,
without limitation, because of a withdrawal of such Registration Statement by BSC prior to the effectiveness thereof pursuant to Section 2.2(v) hereof), (b) after it has become effective, such registration is interfered with for any reason
by any stop order, injunction or other order or requirement of the SEC or any other governmental authority, or as a result of the initiation of any proceeding for such a stop order by the SEC through no fault of BSC and the result of such
interference is to prevent BSC from disposing of such Conversion Shares proposed to be sold in 

  

 4 

 
accordance with the intended methods of disposition, (c) the Company exercises its rights under Section 2.2(x)(ii), and the result is a delay in
the proposed distribution of any Conversion Shares and BSC determines not to sell such Conversion Shares pursuant to such registration as a result of such delay, or (d) the conditions to closing specified in the purchase agreement or
underwriting agreement entered into in connection with any underwritten offering shall not be satisfied or waived with the consent of BSC. 
 (viii) Piggyback Registration 
 Beginning on the date of the issuance of the Conversion Shares, if the Company
proposes to register any shares of Common Stock for itself or any of its stockholders (the stockholders at such time being the “Existing Holders”) under the Securities Act on a Registration Statement on Form S-1, Form S-2 or Form S-3 (or
an equivalent general registration form then in effect), the Company shall give written notice of such proposal at least 15 days before the anticipated filing date, which notice shall include the intended method of distribution of such shares, to
BSC. Such notice shall specify at a minimum the number of shares of Common Stock proposed to be registered, the proposed filing date of such Registration Statement, any proposed means of distribution of such shares and the proposed managing
underwriter, if any. Subject to Section 2.2(ix), upon the written request of BSC, given within 10 days after the receipt of any such written notice by facsimile confirmed by mail (which request shall specify the Conversion Shares intended to be
disposed of by BSC), the Company will use commercially reasonable efforts to include in the Registration Statement the Conversion Shares referred to in BSC’s request; provided, however, that if such Registration Statement relates to a Public
Offering (as below defined), then any participation in such Public Offering by BSC shall be on substantially the same terms as the Company’s (or its other stockholders’) participation therein; and provided further that the amount of
Conversion Shares to be included in any such Public Offering shall not exceed the maximum number which the managing underwriter of such Public Offering considers in its reasonable commercial judgment to be appropriate based on market conditions and
other relevant factors (the “Maximum Number”). BSC shall have the right to withdraw a request to include Conversion Shares in any Public Offering pursuant to this Section 2.2(viii) by giving written notice to the Company of its
election to withdraw such request at least ten business days prior to the proposed effective date of such Registration Statement. For purposes hereof, “Public Offering” shall mean the offer of shares of Common Stock or securities
convertible into or exchangeable for Common Stock on a broadly-distributed basis, not limited to sophisticated investors (except for qualified institutional buyers pursuant to Rule 144A under the Securities Act), pursuant to a firm-commitment or
best-efforts underwriting or purchase arrangement. 
 (ix) Priority in a Piggyback Registration 
 If the lead managing underwriter for any Public Offering to be effected in which BSC seeks registration pursuant to Section 2.2(viii) shall advise the Company and
BSC (each, a “Seller” and, collectively, the “Sellers”) in writing that the number of shares of Common Stock sought to be included in such Public Offering (including those sought to be offered by the Company, those sought to be
offered by BSC pursuant to Section 2.2(viii) and those sought to be offered by Existing Holders) is more than the Maximum Number, the shares of Common Stock to be included in such Public Offering shall be allocated pursuant to the following
procedures: First, the Company shall be entitled to include all of the securities that it has proposed to include; 

  

 5 

 
Second, to the Existing Holder, if any, that requested the Registration Statement be filed for the Public Offering pursuant to a rights agreement between the
Company and such Existing Holder; and Third, to the extent that any other securities may be included without exceeding the Maximum Number, to BSC on a basis no less favorable than that of any other holder of the Company’s securities (other than
the requesting Existing Holder immediately above). 
 (x) Obligations of the Company 
 (i) Whenever the Company is required by the provisions of this Agreement to use commercially reasonable efforts to effect the registration
of any Common Stock under the Securities Act, the Company shall, as expeditiously as possible, (i) prepare and file with the SEC a Registration Statement with respect to such Conversion Shares, and shall use commercially reasonable efforts to
cause such Registration Statement to become effective and to remain effective until the sale of all of the shares of Conversion Shares so registered or, in the case of a “shelf” registration statement filed pursuant to
Section 2.2(vi), for the period specified in that Section; (ii) prepare and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in connection therewith as may be reasonably necessary to
make and to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to the sale or other disposition of all securities proposed to be registered pursuant to such Registration Statement until
the sale of all of the shares of Conversion Shares so registered or, in the case of a “shelf” registration statement filed pursuant to Section 2.2(vi), for the period specified in that Section; and (iii) take all such other
action either necessary or desirable to permit the shares of Conversion Shares held by BSC to be registered and disposed of in accordance with the method of disposition described herein. 
 (ii) Notwithstanding the foregoing, if the Company shall furnish to BSC a certificate signed by its Chairman, Chief Executive Officer or
Chief Financial Officer stating that filing a Registration Statement or maintaining effectiveness of a current Registration Statement would have a serious detrimental effect on the Company or its stockholders in relation to any material financing,
acquisition or other corporate transaction, and the Company has determined in good faith that such registration rights are not in the best interests of the Company and its shareholders, the Company shall be entitled to postpone filing or suspend the
use by BSC of the Registration Statement for a reasonable period of time, but not in excess of 180 consecutive calendar days (a “Blackout Period”). The Company shall be entitled to exercise such suspension rights more than one time in any
calendar year; provided that such exercise shall not prevent BSC from being entitled to at least 180 days of effective registration rights per year and that no suspension period may commence if it is less than 30 calendar days from the prior such
suspension period. 
 (iii) In connection with any Registration Statement pursuant to which BSC shares are being registered,
the following provisions shall apply: 
 (1) The Company shall furnish to BSC, prior to the filing thereof with the SEC, a
copy of any Registration Statement, and each amendment thereof and each amendment or supplement, if any, to the prospectus included therein and shall afford BSC, the managing underwriters, and their respective counsel, if any, a reasonable
opportunity within a reasonable time period to review and comment on copies of all such documents (including a reasonable opportunity to review copies of any documents to be incorporated by reference therein and all exhibits thereto) proposed to be
filed. 
  

 6 

 (2) The Company shall take such action as may be necessary so that: (i) any
Registration Statement and any amendment thereto and any Prospectus forming part thereof and any amendment or supplement thereto (and each report or other document incorporated therein by reference) complies in all material respects with the
Securities Act and the Securities Exchange Act of 1934, as amended, and the respective rules and regulations thereunder, (ii) any Registration Statement and any amendment thereto does not, when it becomes effective, contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and (iii) any prospectus forming part of any Registration Statement, and any amendment or supplement
to such prospectus, does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(3) The Company shall advise BSC and, if requested by BSC, confirm such advice in writing of: 
 a. when a Registration Statement and any amendment thereto has been filed with the SEC and when the Registration Statement or any
post-effective amendment thereto has become effective; 
 b. any request by the SEC for amendments or supplements to the
Registration Statement or the prospectus included therein or for additional information; 
 c. the issuance by the SEC of any
stop order suspending effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; 
 d. the receipt by the Company of any notification with respect to the suspension of the qualification of the securities included therein for sale in any jurisdiction or the initiation of any proceeding for such purpose; and 
 e. the happening of any event that requires the making of any changes in the Registration Statement or the prospectus so that, as of such
date, the Registration Statement and the prospectus do not contain an untrue statement of a material fact and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of the
prospectus, in the light of the circumstances under which they were made) not misleading (which advice shall be accompanied by an instruction to suspend the use of the prospectus relating to such Conversion Shares until the requisite changes have
been made). 
 (4) The Company shall use commercially reasonable efforts to prevent the issuance, and if issued to obtain the
withdrawal, of any order suspending the effectiveness of the Registration Statement relating to such Conversion Shares at the earliest possible time. 
  

 7 

 (5) The Company shall furnish to BSC with respect to the Registration Statement relating
to such Conversion Shares, without charge, such number of copies of such Registration Statement and any post-effective amendment thereto, including financial statements and schedules, and all reports, other documents and exhibits (including those
incorporated by reference) as BSC shall reasonably request. 
 (6) The Company shall furnish to BSC such number of copies of
any prospectus (including any preliminary prospectus and any amended or supplemented Prospectus) relating to such Conversion Shares, in conformity with the requirements of the Securities Act, as BSC may reasonably request in order to effect the
offering and sale of the shares of such Conversion Shares to be offered and sold, but only while the Company shall be required under the provisions hereof to cause the Registration Statement to remain effective, and the Company consents (except
during a Blackout Period or event contemplated by Section 2.2(x)(iii)(3)(c)-(e)) to the use of the prospectus or any amendment or supplement thereto by BSC in connection with the offering and sale of the Conversion Shares covered by the
prospectus or any amendment or supplement thereto. 
 (7) Prior to any offering of securities pursuant to any Registration
Statement, the Company shall use commercially reasonable efforts to register or qualify the Conversion Shares covered by such Registration Statement under the securities or blue sky laws of such states as BSC shall reasonably request, and do any and
all other acts and things either reasonably necessary or advisable to enable BSC to consummate the public sale or other disposition of the Conversion Shares in jurisdictions where BSC desires to effect such sales or other disposition; provided that
the Company shall not be required to take any action that would subject it to the general jurisdiction of the courts of any jurisdiction in which it is not so subject, to qualify as a foreign corporation in any jurisdiction where the Company is not
so qualified or subject it to taxation in any such jurisdiction. 
 (8) In connection with any offering of Conversion Shares
registered pursuant to this Agreement, the Company shall (x) furnish BSC, at the Company’s expense, on a timely basis with certificates free of any restrictive legends representing ownership of the Conversion Shares being sold in such
denominations and registered in such names as BSC shall request and (y) instruct the transfer agent and registrar of the Conversion Shares to release any stop transfer orders with respect to the Conversion Shares and to cooperate with BSC and
its underwriters (if any). 
 (9) Upon the occurrence of any event contemplated by
Section 2.2(x)(iii)(3)(c)-(e) above, the Company shall promptly prepare a post-effective amendment to any Registration Statement or an amendment or supplement to the related prospectus or file any other required document so that, as
thereafter delivered to purchasers of the Conversion Shares included therein, the prospectus will not include an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. If the Company notifies BSC of the occurrence of any Blackout Period or any event contemplated by Section 2.2(x)(iii)(3)(c)-(e) above, BSC shall suspend the use of the prospectus,
until the requisite changes to the prospectus have been made. 
  

 8 

 (10) The Company shall, if requested, promptly include or incorporate in a prospectus
supplement or post-effective amendment to a Registration Statement, such information as the managing underwriters administering an underwritten offering of the Conversion Shares registered thereunder reasonably request to be included therein and to
which the Company does not reasonably object and shall make all required filings of such prospectus supplement or post-effective amendment as soon as practicable after they are notified of the matters to be included or incorporated in such
prospectus supplement or post-effective amendment. 
 (11) If requested, the Company shall enter into an underwriting
agreement with an investment banking firm or firms (in the case of a registration pursuant to Section 2.2(i) or 2.2(vi) selected by BSC) containing representations, warranties, indemnities and agreements then customarily included by an issuer
in underwriting agreements with respect to secondary underwritten distributions, and in connection therewith, if an underwriting agreement is entered into, the Company shall use commercially reasonable efforts to cause the same to contain
indemnification provisions and procedures substantially identical to those set forth in Section 2.2(xii) (or such other provisions and procedures acceptable to the managing underwriters, if any) with respect to all parties to be indemnified
pursuant to Section 2.2(xii) and take all such other actions as are reasonably requested by the managing underwriters for such underwritten offering in order to expedite or facilitate the registration or the disposition of such Conversion
Shares. 
 (12) In the event BSC proposes to conduct an underwritten Public Offering, then the Company shall: (i) make
reasonably available for inspection by BSC and its counsel, any underwriter participating in any distribution pursuant to such Registration Statement, and any attorney, accountant or other agent retained by BSC or any such underwriter, all relevant
financial and other records, pertinent corporate documents and properties of the Company and its subsidiaries as shall be reasonably necessary to enable them to conduct a “reasonable” investigation for purposes of Section 11(a) of the
Securities Act; (ii) cause the Company’s officers, directors and employees to make reasonably available for inspection all relevant information reasonably requested by BSC or any such underwriter, attorney, accountant or agent in
connection with any such Registration Statement, in each case, as is customary for similar due diligence examinations; provided that any information that is designated in writing by the Company, in good faith, as confidential at the time of delivery
of such information shall be kept confidential by BSC, such underwriter, or any such, attorney, accountant or agent, unless such disclosure is made in connection with a court proceeding or required by law, or such information becomes available to
the public generally or through a third party without an accompanying obligation of confidentiality; (iii) obtain opinions of counsel to the Company and updates thereof (which counsel and opinions (in form, scope and substance) shall be
reasonably satisfactory to the managing underwriters, if any), addressed to BSC and the underwriters, if any, covering such matters as are customarily covered in opinions requested in underwritten offerings and such other matters as may be
reasonably requested by BSC and underwriters (it being agreed that the matters to be covered by such opinion or written statement by such counsel delivered in connection with such opinions shall include in customary form, without limitation, as of
the date of the opinion and as of the effective date of the Registration Statement or most recent post-effective amendment thereto, as the case may be, the absence from such Registration Statement and the prospectus included therein, as then amended
or supplemented, including the documents 

  

 9 

 
incorporated by reference therein, of an untrue statement of a material fact or the omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading); (iv) use its commercially reasonable efforts to obtain “cold comfort” letters and updates thereof from the independent public accountants of the Company (and, if necessary,
any other independent public accountants of any subsidiary of the Company or of any business acquired by the Company for which financial statements and financial data are, or are required to be, included in the Registration Statement), addressed to
BSC and the underwriters, if any, in customary form and covering matters of the type customarily covered in “cold comfort” letters in connection with primary underwritten offerings; and (v) deliver such documents and certificates as
may be reasonably requested by BSC and the managing underwriters, if any, and with any customary conditions contained in the underwriting agreement or other agreement entered into by the Company. The foregoing actions set forth in clauses (iii),
(iv) and (v) of this Section 2.2(x)(iii)(12) shall be performed at each closing under any underwritten offering to the extent required thereunder. 
 (13) The Company will use commercially reasonable efforts to cause such Conversion Shares to be admitted for quotation on the NASDAQ
Capital Market (“NASDAQ”) or other stock exchange or trading system on which the Common Stock primarily trades on or prior to the effective date of any Registration Statement hereunder. 
 (14) The Company shall use commercially reasonable efforts to take all other steps reasonably necessary to effect the registration,
offering and sale of the Conversion Shares covered by a Registration Statement contemplated hereby and enter into any other customary agreements and take such other actions, including participation of senior management in “roadshows” as
are reasonably required in order to expedite or facilitate the disposition of such Conversion Shares, and the Company shall secure the participation of its senior management for such purposes. 
 (iv) With a view to making available the benefits of certain rules and regulations of the SEC which may at any time permit the sale of the
Conversion Shares to the public without registration, the Company agrees to: 
 (1) Make and keep public information
available, as those terms are understood and defined in and interpreted under Rule 144, at all times; 
 (2) During such time
as BSC holds Conversion Shares, furnish to BSC upon request: (i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company,
and (iii) such other reports and documents of the Company as BSC may reasonably request in availing itself of any rule or regulation of the SEC allowing BSC to sell any such securities without registration. 
 (xi) Expenses of Registration 
 (i) Except as provided in subsection (ii) of this Section, all fees and expenses incident to the registration and sale of Conversion Shares shall be borne by the Company whether or not a Registration Statement is
filed or becomes effective, including, 

  

 10 

 
without limitation, (i) all registration, qualification and filing fees (including, without limitation, (A) fees with respect to filings required
to be made with NASDAQ and (B) fees and expenses of compliance with state securities or blue sky laws (including, without limitation, fees and disbursements of counsel for the Company or the underwriters, or both, in connection with blue sky
qualifications of the Conversion Shares)), (ii) messenger and delivery expenses, word processing, duplicating and printing expenses (including, without limitation, expenses of printing certificates for Conversion Shares in a form eligible for
deposit with The Depository Trust Company, and the relevant fees and expenses of the Company’s transfer agent, printing preliminary prospectuses, prospectuses, prospectus supplements, including those delivered to or for the account of BSC as
provided in this Agreement, and printing or preparing any underwriting agreement, agreement among underwriters and related syndicate or selling group agreements, pricing agreements and blue sky memoranda), (iii) fees and disbursements of
counsel for the Company, (iv) fees and disbursements of all independent certified public accountants for the Company (including, without limitation, the expenses of any “comfort letters” required by or incident to such performance),
(v) the fees and expenses of any “qualified independent underwriter” or other independent appraiser participating in an offering pursuant to Section 3 of Rule 2720 of the Conduct Rules of the NASD (unless such qualified
independent underwriter is required as a result of an affiliation between an underwriter selected by BSC and BSC, in which case such fees and expenses will be borne by BSC), (vi) Securities Act liability insurance, if the Company so desires
such insurance, (vii) all out-of-pocket expenses of the Company (including, without limitation, expenses incurred by the Company, its officers, directors, employees and agents performing legal or accounting duties or preparing or participating
in “roadshow” presentations or of any public relations, investor relations or other consultants or advisors retained by the Company in connection with any roadshow, including travel and lodging expenses of such roadshows), and
(viii) the fees and expenses incurred in connection with the quotation or listing of shares of Common Stock on any securities exchange or automated securities quotation system. The fees and expenses set forth in this Section 2.2(xi)(i) are
collectively referred to as “Registration Expenses”. 
 (ii) BSC shall pay all underwriting discounts and
commissions or broker’s commissions incurred in connection with the sale or other disposition of Conversion Shares for or on behalf of BSC’s account as well as the fees and expenses of BSC’s counsel. 
 (iii) BSC shall pay all out-of-pocket Registration Expenses reasonably incurred by the Company unless a Registration Statement shall be
effected pursuant to Section 2.2(i) or 2.2(vi) within 270 days after a withdrawal as provided in Section 2.2(v). 
 (xii) Indemnification 
 (i) The Company shall, without limitation as to time, indemnify and hold harmless, to
the fullest extent permitted by law, BSC and any underwriter participating in the distribution, their respective officers, directors, partners and agents and employees of each of them, each person who controls BSC or any such underwriter (within the
meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act) and the officers, directors, partners, agents and employees of each such controlling person (individually, a “BSC Indemnified Person”) from and
against any and all losses, claims, damages, liabilities, costs (including, without limitation, costs of investigating, preparing to defend, defending and appearing as a 

  

 11 

 
third-party witness and attorneys’ fees and disbursements) and expenses, including any amounts paid in respect of any settlements (collectively,
“Losses”), joint or several, without duplication, as incurred, arising out of or based upon any untrue or alleged untrue statement of a material fact contained in any Registration Statement, prospectus or form of prospectus, or in any
amendment or supplements thereto or in any preliminary prospectus, or arising out of or based upon, in the case of the Registration Statement or any amendments thereto, any omission or alleged omission of a material fact required to be stated
therein or necessary to make the statements therein not misleading, and, in the case of the prospectus or form of prospectus, or in any amendments or supplements thereto, or in any preliminary prospectus, any omission or alleged omission of a
material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading except, in either case, (i) to the extent, but only to the extent, that such
untrue or alleged untrue statement or omission or alleged omission has been made therein in reliance upon and in conformity with information furnished in writing to the Company by such BSC Indemnified Person expressly for use therein and
(ii) if the person asserting any such Losses who purchased the Conversion Shares which are the subject thereof did not receive a copy of an amended preliminary prospectus or the final prospectus (or the final prospectus as amended or
supplemented) at or prior to the written confirmation of the sale of such Conversion Shares to such person (if it is determined that the Company has provided such preliminary prospectus and it was the responsibility of such BSC Indemnified Person to
provide such person with a current copy of the prospectus or amended or supplemented prospectus, as the case may be) and the untrue statement or alleged untrue statement or omission or alleged omission of a material fact made in such preliminary
prospectus was corrected in the amended preliminary prospectus or the final prospectus (or the final prospectus as amended and supplemented). 
 (ii) In connection with any Registration Statement in which BSC as a holder of Conversion Shares is participating, BSC shall, without limitation as to time, indemnify and hold harmless, to the fullest extent permitted
by law, the Company, any underwriter participating in the distribution and their respective directors, officers, agents and employees, each person who controls the Company or any such underwriter (within the meaning of Section 15 of the
Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling person (individually, a “Company Indemnified Person”), from and against any and all Losses, as incurred, arising
out of or based upon (i) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, prospectus, or form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or
arising out of or based upon, in the case of the Registration Statement or any amendments thereto, any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, and, in
the case of the prospectus, or form of prospectus, or in any amendments or supplements thereto, or in any preliminary prospectus, any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, in either case, to the extent, but only to the extent, that such untrue or alleged untrue statement or omission or alleged omission has been made therein in
reliance upon and in conformity with information furnished in writing to the Company by BSC expressly for use therein or (ii) the failure of BSC (if it is determined that it was the responsibility of BSC) at or prior to the written confirmation
of the sale of the Conversion Shares to send or deliver a copy of an amended preliminary prospectus or the final prospectus (or the final prospectus as amended 

  

 12 

 
or supplemented) to the person asserting any such Losses who purchased the Conversion Shares which are the subject thereof and the untrue statement or
alleged untrue statement or omission or alleged omission of a material fact made in such preliminary prospectus was corrected in the amended preliminary prospectus or the final prospectus (or the final prospectus as amended and supplemented).

 (iii) Each BSC Indemnified Person and Company Indemnified Person (each an “Indemnified Person”) shall give prompt
notice to the party or parties from which such indemnity is sought (the “Indemnifying Parties”) of the commencement of any action or proceeding (including any governmental investigation) (collectively “Proceedings” and
individually a “Proceeding”) with respect to which such Indemnified Person seeks indemnification or contribution pursuant hereto; provided, however, that the failure so to notify the Indemnifying Parties shall not relieve the Indemnifying
Parties from any obligation or liability except to the extent that the Indemnifying Party was otherwise unaware of such Proceeding and the Indemnifying Parties shall have been materially prejudiced by such failure. The Indemnifying Parties shall
have the right, exercisable by giving written notice to an Indemnified Person promptly after the receipt of written notice from such Indemnified Person of such Proceeding, to assume, at the Indemnifying Parties’ expense, the defense of any such
proceeding, with counsel reasonably satisfactory to such Indemnified Person and shall pay as incurred the fees and disbursements of such counsel related to such Proceeding; provided, however, that an Indemnified Person or Indemnified Persons (if
more than one such Indemnified Person is named in any Proceeding) shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
such Indemnified Person or Indemnified Persons unless: (i) the Indemnifying Party or parties agree to pay such fees and expenses; or (ii) the Indemnifying Parties fail promptly to assume the defense of such Proceeding or fail promptly to
employ counsel reasonably satisfactory to such Indemnified Person or Indemnified Persons; or (iii) the named parties to any such action (including any impleaded parties) include both an Indemnified Person and the Indemnifying Party, and the
Indemnified Person or Indemnified Persons shall have been advised by counsel that there may be a conflict between the positions of the Indemnifying Party or an Affiliate of the Indemnifying Party and such Indemnified Person or Indemnified Persons in
conducting the defense of such action or proceeding or that there may be legal defenses available to such Indemnified Person or Indemnified Persons different from or in addition to those available to the Indemnifying Party or such Affiliate, in
which case, if such Indemnified Person or Indemnified Persons notifies the Indemnifying Parties in writing that it elects to employ separate counsel at the expense of the Indemnifying Parties, the Indemnifying Parties shall not have the right to
assume the defense thereof and such counsel shall be at the expense of the Indemnifying Parties, it being understood, however, that the Indemnifying parties shall not, in connection with any one such Proceeding or separate but substantially similar
or related Proceedings in the same jurisdiction, arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys (together with appropriate local counsel) at
any time for such Indemnified Person or Indemnified Persons. Whether or not such defense is assumed by the Indemnifying Parties, such Indemnifying parties or Indemnified Person or Indemnified Persons will not be subject to any liability for any
settlement made without its or their consent (but such consent will not be unreasonably withheld). No Indemnifying Party shall be liable for any settlement of any such action or proceeding effected without its written consent, but if settled with
its written consent 

  

 13 

 
each Indemnifying Party jointly and severally agrees, subject to the exception and limitations set forth above, to indemnify and hold harmless each
Indemnified Person from and against any loss or liability by reason of such settlement. No indemnification provided for in Section 2.2(xii)(i) or 2.2(xii)(ii) shall be available to any party who shall fail to give notice as provided in this
Section 2.2(xii)(iii) if the party to whom notice was not given was unaware of the proceeding to which such notice would have related and was materially prejudiced by the failure to give such notice, but the failure to give such notice shall
not relieve the indemnifying party or parties from any liability which it or they may have to an Indemnified Person otherwise than on account of the provisions of Section 2.2(xii)(i) or 2.2(xii)(ii). No Indemnifying party shall, without the
consent of the Indemnified Person, consent to entry of any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Person of a release from all liability in respect of such claim
or litigation. 
 (iv) If the indemnification provided for in this Section 2.2(xii) is unavailable to an Indemnified
Person or is insufficient to hold such Indemnified Person harmless for any Losses in respect to which this Section 2.2(xii) would otherwise apply by its terms, except by reasons of Section 2.2(xii)(i)(i) or 2.2(xii)(i)(ii) hereof or the
failure of the Indemnified Person to give notice as required in Section 2.2(xii)(iii) hereof (provided that the Indemnifying Party was unaware of the proceeding to which such notice would have related and was materially prejudiced by the
failure to give such notice), then each applicable Indemnifying Party, in lieu of indemnifying such Indemnified Person, shall have an obligation to contribute to the amount paid or payable by such Indemnified Person as a result of such Losses, in
such proportion as is appropriate to reflect the relative fault of the Indemnifying Party, on the one hand, and such Indemnified Person, on the other hand, in connection with the actions, statements or omissions that resulted in such Losses as well
as any other relevant equitable considerations. The amount paid or payable by a party as a result of any Losses shall be deemed to include any legal or other fees or expenses incurred by such party in connection with any Proceeding, to the extent
such party would have been indemnified for such expenses if the indemnification provided for in Section 2.2(xii)(i) or Section 2.2(xii)(ii) were available to such party. The parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 2.2(xii)(iv) were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to above. No Person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 
 (v) The indemnity, contribution and expense reimbursement obligations under this Section 2.2(xii) shall be in addition to any
liability each indemnifying party may otherwise have and shall remain operative and in full force and effect regardless of any investigation made by or on behalf of any Indemnified Person. In the event of any conflict between the indemnification and
contribution terms as herein set forth and as set forth in any underwriting agreement entered pursuant hereto, the underwriting agreement shall control. The obligations of the Company and BSC under this Section 2.2(xii) shall survive the
completion of any offering of Conversion Shares in a Registration Statement. 
 2.3 Additional Restrictions on Transfer of Conversion
Shares. BSC will make no transfer of the Conversion Shares that is in violation of the Securities Act or any state securities law or regulation. BSC agrees that in no event will BSC sell, transfer, or otherwise dispose of 
  

 14 

 
any of the Conversion Shares (other than pursuant to an effective registration statement under the Securities Act and applicable state securities laws),
unless and until BSC has first furnished to the Company an opinion, reasonably satisfactory to the Company and its legal counsel, to the effect that such transfer may be made without registration under the Securities Act and all applicable state
securities laws. 
 2.4 Legends. BSC agrees that stop transfer instructions will be given to the Company’s transfer agent (or
noted on the appropriate records of the Company) and that there has been placed on BSC’s certificate(s) representing the Conversion Shares a legend in substantially the following form: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR UNDER
THE PROVISIONS OF ANY APPLICABLE STATE SECURITIES LAWS, BUT HAVE BEEN ACQUIRED BY THE HOLDER HEREOF FOR PURPOSES OF INVESTMENT AND IN RELIANCE ON STATUTORY EXEMPTIONS UNDER THE 1933 ACT AND UNDER APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES
MAY NOT BE SOLD, PLEDGED, TRANSFERRED OR ASSIGNED, EXCEPT IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER PROVISIONS OF THE 1933 ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT THEREUNDER; AND
IN THE CASE OF AN EXEMPTION, ONLY IF THE ISSUER HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION OF ANY SUCH SECURITIES. 
 Any assignment or endorsement of the certificate(s) representing the Conversion Shares which is in violation of the restrictions on transfer provided
above and elsewhere herein will not be recognized by the Company nor will any assignee or endorsee of such shares be recognized as the owner thereof by the Company. 
 2.5 Additional Documents and Assurances. If deemed necessary by the Company or its counsel, BSC shall execute and deliver, or cause to be executed and delivered, all such additional instruments and documents as
are required to best effectuate the purposes and intent of this Agreement, including the cancellation of the Preferred Shares as of the Effective Date. 
  

 15 

	3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

 The
Company hereby represents and warrants to BSC as of the date hereof and as of the Effective Time the following: 
 3.1 Organization.
The Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to own and operate its properties and assets and to carry on its business
as now conducted and as presently proposed to be conducted. 
 3.2 Authorization. The Company has the right, power and capacity to
execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement by the Company, and the consummation of the transactions
contemplated hereby, have been duly authorized by all necessary corporate and stockholder action on the part of the Company. This Agreement has been duly and validly executed and delivered by the Company and constitutes the Company’s legal,
valid and binding obligation, enforceable in accordance with its terms, except as limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’
rights generally, and (ii) laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 
 3.3 No Conflict. The execution and delivery of this Agreement by the Company, the consummation of the transactions contemplated herein by the Company, and the performance of the covenants and agreements of the Company will not, with
or without the giving of notice or the lapse of time, or both: (A) violate or conflict with any of the provisions of any charter document or bylaw of the Company; or (B) violate, conflict with or result in a breach or default under or
cause termination of any term or condition of any mortgage, indenture, contract, license, permit, instrument, trust document, will, or other agreement, document or instrument to which the Company is a party or by which the Company or its properties
may be bound; or (C) violate any provision of law, statute, regulation, court order or ruling of any governmental authority to which the Company is a party or by which it or its properties may be bound; or (D) result in the creation or
imposition of any lien, claim, charge, restriction, security interest or encumbrance of any kind whatsoever upon any asset of the Company. 
 3.4 Public Filings. The Company has filed all forms, reports and documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (“Exchange Act”),
during the twelve (12) months preceding the date of this Agreement. As of their respective filings dates, such reports (a) were prepared in accordance with either the requirements of the Securities Act or the Exchange Act, as the case may
be, and the rules and regulations of the SEC promulgated thereunder, and (b) did not, at the time they were filed, or, if amended, as of the date of such amendment, contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. 
  

 16 

 3.5 Issued Shares. The Conversion Shares, when issued and delivered in accordance with the terms
hereof for the consideration expressed herein, shall be duly and validly issued, fully paid, and nonassessable. 
 3.6 Government
Approvals. Except for filings and/or notices necessary to comply with the Securities Act and state securities or “blue sky” laws, no consent, approval, qualification, order or authorization of, or filing with, any local, state, or
federal governmental authority is required on the part of the Company by virtue of the Company’s execution and delivery of this Agreement or the consummation of any of the transactions contemplated herein. 
  

	4.	REPRESENTATIONS AND WARRANTIES OF BSC 

 BSC hereby
represents and warrants to the Company as of the date hereof and the Effective Time the following: 
 4.1 Organization. BSC is a
corporation duly organized, validly existing and in good standing under the laws of its state of incorporation and has all requisite corporate power and authority to own and operate its properties and assets and to carry on its business as now
conducted and as presently proposed to be conducted. 
 4.2 Authorization. BSC has the right, power and capacity to execute and
deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement by BSC, and the consummation of the transactions contemplated hereby, have
been duly authorized by all necessary corporate and shareholder action on the part of BSC. This Agreement has been duly and validly executed and delivered by BSC and constitutes BSC’s legal, valid and binding obligation, enforceable in
accordance with its terms, except as limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) laws relating to
the availability of specific performance, injunctive relief or other equitable remedies. 
 4.3 No Conflict. The execution and
delivery of this Agreement by BSC, the consummation of the transactions contemplated herein by BSC, and the performance of the covenants and agreements of BSC will not, with or without the giving of notice or the lapse of time, or both:
(A) violate or conflict with any of the provisions of any charter document or bylaw of BSC; or (B) violate, conflict with or result in a breach or default under or cause termination of any term or condition of any mortgage, indenture,
contract, license, permit, instrument, trust document, will, or other agreement, document or instrument to which BSC is a party or by which it or its properties may be bound; or (C) violate any provision of law, statute, regulation, court order
or ruling of any governmental authority to which BSC is a party or by which it or its properties may be bound; or (D) result in the creation or imposition of any lien, claim, charge, restriction, security interest or encumbrance of any kind
whatsoever upon any asset of BSC. 
 4.4 Preferred Shares. BSC is the sole owner and holder of the Preferred Shares and BSC has not
assigned or transferred, or purported to assign or transfer, to anyone whatsoever all or any portion of or interest in the Preferred Shares. BSC has no knowledge of any party having an interest in the Preferred Shares. 
  

 17 

 4.5 Termination of Rights and Preferences of Preferred Shares. In accordance with Section 1.3
of this Agreement, BSC understands that in exchange for the Conversion Shares, BSC’s rights and preferences related to the Preferred Shares are forever terminated, and BSC can no longer enforce any rights or preferences whatsoever with regard
to the Preferred Shares. Additionally, BSC acknowledges and agrees that any and all rights to receive dividends with respect to the Preferred Shares, whether past or future, declared or accrued and undeclared, are hereby extinguished. 
 4.6 Investment Representations and Intent. 
 (i) Accredited Investor. BSC is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act, and is experienced in evaluating and investing in companies such
as the Company, and has such expertise and knowledge in financial and business matters so as to be able to evaluate the merits and risks of an investment in the Company. BSC is able to bear the economic risk of investment in the Conversion Shares,
has adequate means of providing for BSC’s current needs and contingencies and has no need for liquidity with respect to the Conversion Shares. 
 (ii) Investment Decision. BSC is not acquiring the Conversion Shares based upon any representation, oral or written, by the Company or any representative of the Company with respect to the future value of,
income from, or tax consequences relating to the Conversion Shares, but rather upon an independent examination and judgment as to the prospects of the Company. Further, BSC acknowledges that no federal or state administrative entity responsible for
securities registration or enforcement has made any recommendation or endorsement of the Conversion Shares or any findings as to the fairness of an investment in the Conversion Shares. 
 (iii) Access to Information. BSC has received and reviewed all the information BSC considers necessary or appropriate for deciding
whether to acquire the Conversion Shares. The Company has made available to BSC all records, documents, books of account and other materials or information requested by BSC which the Company has in its possession or are reasonably obtainable. BSC
has had the opportunity to ask questions of, and receive answers from, the executive officers of the Company concerning the terms and conditions of BSC’s purchase and the Company’s business, management, financial affairs, and to obtain
additional information necessary to verify the accuracy of any information furnished to BSC. BSC has had the opportunity to request additional information and there has been no information requested that has not been provided to BSC. In making the
decision to convert, BSC has relied upon BSC’s own independent investigations of the Company. 
 (iv) Investment
Intent. BSC is acquiring the Conversion Shares for its own account for investment and not with a view to, or resale in connection with, any distribution of such Conversion Shares, within the meaning of the Securities Act, and BSC has no present
intention of reselling, assigning or otherwise disposing of all or any shares of the Conversion Shares. 
  

 18 

 (v) No Registration. BSC understands that the Conversion Shares have not been
registered under the Securities Act or the securities laws of any state and that Conversion Shares will be issued by the Company in reliance upon exemptions from the registration requirements of such acts. BSC understands that the Company is under
no obligation to register the Conversion Shares under the Securities Act or any state securities act or to take any other action necessary to comply with an available exemption or regulation under any such acts (including Rule 144 under the
Securities Act) in order to permit BSC to sell, transfer or otherwise dispose of the Conversion Shares. 
 BSC understands and agrees that
all representations and agreements made herein form, in part, the basis for the exemptions under the Securities Act and the applicable state securities laws relied upon by the Company in issuing the Conversion Shares and that in issuing the
Conversion Shares the Company has relied on all representations and agreements of BSC contained herein. Acceptance by BSC of the certificate or certificates representing the Conversion Shares shall constitute a confirmation by BSC that all such
representations and agreements remain true and correct as of the date of acceptance of such certificate(s) by BSC. 
  

	5.	MISCELLANEOUS. 

 5.1 Entire Agreement. This
Agreement (and the documents referenced herein) constitutes the entire agreement among the parties and supersedes any prior understanding or agreement between them with respect to the subject matter hereof; provided, however, that this
provision is not intended to abrogate any other written agreement between the parties executed with or after this Agreement. 
 5.2
Amendments and Waivers. No amendment, supplement, alteration or modification to the terms of this Agreement shall be binding unless the same shall be in writing and duly executed by the parties hereto. No waiver of any provision hereof will be
valid or binding on the parties hereto unless such waiver is in writing and signed by or on behalf of the parties hereto, and no waiver on one occasion shall be deemed to be a waiver of the same or any other provision hereof in the future.

 5.3 Survival of Warranties. The warranties, representations and covenants of the Company and BSC contained in or made pursuant to
this agreement shall survive the execution and delivery of this Agreement and shall expire on the third anniversary of the Effective Time. 
 5.4 Assignment; Successors and Assigns. No party hereto may assign all or any of its rights, duties or obligations hereunder to any other person without the prior written consent of the other party, except for assignments which occur
by operation of law. Except as otherwise provided herein, the terms, conditions and obligations of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in
this Agreement. 
  

 19 

 5.5 Governing Law. This Agreement shall be governed by and construed under the laws of the State
of Delaware. 
 5.6 Counterparts and Facsimile. This Agreement may be executed in multiple counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed and delivered by facsimile, and a facsimile copy of this Agreement shall be deemed an original. 
 5.7 Headings. The titles, subtitles and other headings used in this Agreement are for convenience only and shall not be considered in construing
or interpreting this Agreement. 
 5.8 Notices. Unless otherwise provided, all notices and other communications required or permitted
under this Agreement shall be in writing and shall be mailed by United States first-class mail, postage prepaid, sent by facsimile (upon confirmation of the successful transmission thereof) or delivered personally by hand or by a nationally
recognized courier addressed to the party to be notified at the address or facsimile number set forth below or at such other address or facsimile number as such party may designate by ten (10) days advance written notice to the other parties
thereto. All such notices and other written communications shall be effective on five (5) days after the date of mailing, or the date of confirmed facsimile transmission or the date of delivery. 
  

			
	To the Company:	  	 Richard E. Otto
 Chief Executive Officer
 Corautus Genetics Inc.
 70 Mansell Center, Suite 100
 Roswell, Georgia 30076
 Fax: (404) 526-6200

		
	with a copy to:	  	 Robert E. Tritt, Esq.
 McKenna, Long &
Aldridge LLP
 303 Peachtree Street, N.E.
 Suite 5300

Atlanta, GA 30308
 Fax: (404) 527-4198

		
	to BSC:	  	 Chief Financial Officer
 Boston Scientific Corporation

 One Boston Scientific Place
 Natick, MA 01760-1537

Fax: (508) 650- 8956

		
	with a copy to:	  	 Craig Smith, Esq.
 Assistant General
Counsel
 Boston Scientific Corporation
 One Boston Scientific
Place
 Natick, MA 01760-1537
 Fax: (508) 650-
8960

  

 20 

 From and after the Effective Time, all notices and other communications described above shall no longer
be provided to McKenna, Long & Aldridge LLP or to the Company at the address provided above, but shall be provided to the Company and its counsel at the addresses provided below. 

			
		
	To the Company:	  	 Chief Financial Officer
 VIA Pharmaceuticals, Inc.

 750 Battery Street, Suite 330
 San Francisco CA
94111
 Fax: (415) 283-2201

		
	with a copy to:	  	 Michael A. Pucker
 Latham & Watkins
LLP
 233 South Wacker Drive
 Suite 5800
 Chicago, IL 60606-6401
 Fax: (312) 993-9767

 5.9 Finder’s Fees. Each party represents that it neither is nor will be obligated for
any finder’s fee or commission in connection with the transactions described herein. BSC agrees to indemnify and to hold the Company harmless from any and all liability for any commission or compensation in the nature of a finder’s fee
(and the costs and expenses of defending against such liability or asserted liability) for which BSC or any of its agents or representatives are responsible. The Company agrees to indemnify and hold harmless BSC from any liability for any commission
or compensation in the nature of a finder’s fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees, or representatives is responsible. 
 5.10 Expenses. Each party shall pay all costs and expenses it incurs with respect to the negotiation, execution, delivery, and performance of this
Agreement. 
 5.11 Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this
Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs, and disbursements actually incurred, in addition to any other relief to which such party may be entitled. 
 5.12 Tax Advice. BSC has sought and received independent tax advice concerning the federal income tax consequences of the transactions described
in this Agreement, and has not received nor relied on any tax advice from the Company or its counsel in deciding to consummate the transactions contemplated herein. 
 5.13 Severability. If any one or more of the provisions of this Agreement are held by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision shall be excluded
from this Agreement and the remaining provisions of this Agreement shall not in any way be affected or impaired thereby and shall be enforceable in accordance with 
 its terms, except that this Agreement shall not be reformed in any manner that will deny any party the essential benefits of this Agreement unless such party waives in writing its rights to such benefits. 
  

 21 

 IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first
above written. 
  

			
	 COMPANY:
  
 CORAUTUS GENETICS INC.

		
	By:	 	/s/ Richard E. Otto
	Name:	 	Richard E. Otto
	Its:	 	Chief Executive Officer

  

			
	 BSC:
  
 BOSTON SCIENTIFIC
 CORPORATION

		
	By:	 	/s/ Lawrence C. Best
	Name:	 	Lawrence C. Best
	Its:	 	 Vice President for Finance and
 Administration, Chief
Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]